<?xml version="1.0" encoding="UTF-8"?>
<p>In summary, protocols should guarantee the feasibility of performing PCI in facilities approved for treatment of Covid-19 patients, avoiding potentially harmful thrombolysis, in compliance with adequate safety measures to protect healthcare workers (see after), since primary PCI should remain the default strategy in patients with clear evidence of a STEMI, as clearly stated in American guidelines on the management of AMI during the Covid-19 pandemic [
 <xref rid="B89-jcm-09-01683" ref-type="bibr">89</xref>]. An efficacious strategy could be to organize separated catheterization labs and subsequently CCUs or cardiology wards for patients with and without SARS-CoV-2 infections, although this may be possible only in high volume hospitals. On 3 April 2020, SCAI and the Canadian Association of Interventional Cardiology (CAIC) announced the formation of the North American Covid-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI) [
 <xref rid="B92-jcm-09-01683" ref-type="bibr">92</xref>], which hopefully will tell us more about this topic, since further data are needed to detect and characterize patients with STEMI and Covid-19 and to optimize treatment.
</p>
